Arvinas Announces Positive Phase 1 Data for ARV-102 in Parkinson’s Disease
Arvinas Reports Positive Phase 1 Clinical Data for ARV-102 in Parkinson’s Disease
New Haven, CT, March 18, 2026 – Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company focused on targeted protein degradation, announced the release of positive Phase 1 clinical trial data for its investigational drug ARV-102. The data were presented at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2026) in Copenhagen, Denmark.
Key Highlights from the Report
- ARV-102 is a first-in-class, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) designed to cross the blood-brain barrier and specifically target and degrade leucine-rich repeat kinase 2 (LRRK2), a protein implicated in Parkinson’s disease and other neurodegenerative disorders.
- Phase 1 data showed more than 50% degradation of LRRK2 in the cerebrospinal fluid (CSF) of patients with Parkinson’s disease treated for 28 days.
- ARV-102 also led to reductions in endolysosomal and neuroinflammatory biomarkers associated with Parkinson’s disease and progressive supranuclear palsy (PSP).
- ARV-102 was well tolerated across all dose levels following 28 days of once-daily dosing.
- Pharmacology and changes in peripheral biomarkers in patients with Parkinson’s disease were consistent with those observed in healthy volunteers.
Implications for Shareholders and Potential Price Sensitivity
- This is the first time such a level of LRRK2 degradation and biomarker modulation has been demonstrated in humans using a targeted protein degrader. Arvinas believes these results have not been achieved by LRRK2 inhibitors and represent a significant milestone in the development of disease-modifying therapies for Parkinson’s disease and related disorders.
- The company plans to continue clinical development of ARV-102 for neurodegenerative diseases associated with LRRK2 and endolysosomal dysfunction.
- Pending regulatory feedback, Arvinas intends to initiate a Phase 1b trial in progressive supranuclear palsy (PSP) in Q2 2026, with the potential to start a registrational trial in late 2026. The company will also evaluate further development in Parkinson’s disease.
- Progressive supranuclear palsy is a rare, rapidly progressing neurodegenerative disease with high unmet need. The company’s focus on this indication, along with Parkinson’s disease, expands its addressable market and could enhance shareholder value if successful.
- Arvinas is advancing several other clinical-stage assets, including ARV-806 (KRAS G12D for cancers), ARV-393 (BCL6 for non-Hodgkin lymphoma), ARV-27 (polyQ-AR for skeletal muscle disorders), and vepdegestrant (estrogen receptor for ER+/HER2- breast cancer).
- These new data and pipeline developments are likely to be seen as important, potentially price-moving events for Arvinas stock.
Forward-Looking Statements and Risks
- This announcement contains forward-looking statements about the potential of ARV-102, including its plans for further trials and potential expansion into additional neurodegenerative diseases. Actual results could differ materially due to clinical, regulatory, or commercial risks.
- Key risks include uncertainties in clinical trial outcomes, regulatory feedback, competitive landscape, intellectual property protection, need for additional capital, and general market conditions.
- Shareholders are encouraged to review the company’s filings with the U.S. Securities and Exchange Commission for a more detailed discussion of risks.
Contact Information
Disclaimer: This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Investors should perform their own due diligence and consult with their financial advisors before making any investment decisions. The author and publisher are not responsible for any investment actions taken based on this article.
View ARVINAS, INC. Historical chart here
